Where Biotech Shines

Where Biotech Shines

The Swiss Biotech Report 2021 portrays this unique sector in Switzerland whose relevance has significantly increased in times of Covid-19.

As the latest edition of the Swiss Biotech Report entitled “Agility, Leadership and Innovation in the time of Covid-19” highlights, Switzerland is home to a vibrant and globally unique Biotech sector. At its heart lies the Swiss Stock Exchange which has helped companies and their investors manage the volatility shocks over the course of the past year.

Access to Capital Enables Future Growth
During the crisis and in times of great uncertainty which was accompanied by high market volatilities in 2020, the Swiss Stock Exchange played an important role for Biotech companies, granting them ongoing access to capital in order to strengthen their capital structure, to further develop their product pipeline or to advance into new areas such as the research and development of antiviral compounds to combat the corona pandemic.

Swiss Biotech Sector Gains in Importance
In 2020, Swiss Biotech companies (both publicly listed and privately held) raised a total of CHF 3.44bn on the Swiss Stock Exchange, which is a record and almost a threefold increase compared to 2019. The increased interest from investors in this sector has also been impressively reflected in trading activity. Trading volumes on the Swiss Stock Exchange have increased by 177% in 2020 compared to 2019 and the free float market capitalizations of all SIX-listed biotech companies went up by 30% over the same period.

Exemplary Agility, Innovation and Leadership
As an integral part of the Swiss life sciences ecosystem, the Swiss Stock Exchange once again contributed an article to this year’s report: “SIX listed biotechs light up an exceptional trading year”. Using the example of Zurich-based Molecular Partners, the article emphasizes the high level of resilience that Biotech companies have demonstrated in a challenging year and how they have been able to advance their product pipelines and innovations.

Our Sector Focus, Your Advantage
Life sciences companies listed on the Swiss Stock Exchange benefit from outstanding visibility among investors and the media as well as broad coverage by analysts specialising in this sector. Thanks to comprehensive sector-specific know-how, companies can expect a stable market environment and an attractive valuation. Our website provides an overview of all information and services for issuers.

About the Swiss Biotech Association
Founded in 1998, the Swiss Biotech Association represents the interests of the Swiss biotech industry. To support its members, the association works to secure favorable framework conditions and facilitate access to talents, novel technologies and financial resources.